Therapeutic strategies for cancer treatment related peripheral neuropathies

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OPINION STATEMENT: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with multiple chemotherapeutic agents. CIPN may have a detrimental impact on patients' quality of life and functional ability, as well as result in chemotherapy dose reductions. Although symptoms of CIPN can improve with treatment completion, symptoms may persist. Currently, the treatment options for CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has the most evidence supporting its use in the treatment of CIPN. Other agents with potential benefit for the treatment of established CIPN include gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel consisting of the combination of amitriptyline, ketamine, and baclofen; none of these, however, has been proven to be helpful and ongoing/future studies may well show that they are not beneficial. The use of these agents is often based on their efficacy in the treatment of non-CIPN neuropathic pain, but this does not necessarily mean that they will be helpful for CIPN-related symptoms. Other nonpharmacologic interventions including acupuncture and Scrambler therapy are supported by positive preliminary data; however, further larger, placebo-controlled trial data are needed to confirm or refute their effectiveness.

Original languageEnglish (US)
Pages (from-to)567-580
Number of pages14
JournalCurrent Treatment Options in Oncology
Volume15
Issue number4
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Peripheral Nervous System Diseases
Drug Therapy
Therapeutics
Acupuncture Therapy
Baclofen
Amitriptyline
Tricyclic Antidepressive Agents
Ketamine
Neuralgia
Gels
Placebos
Quality of Life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic strategies for cancer treatment related peripheral neuropathies. / Pachman, Deirdre R.; Watson, James; Loprinzi, Charles Lawrence.

In: Current Treatment Options in Oncology, Vol. 15, No. 4, 01.12.2014, p. 567-580.

Research output: Contribution to journalArticle

@article{31f1eb75fc334892aff786f91dd62d53,
title = "Therapeutic strategies for cancer treatment related peripheral neuropathies",
abstract = "OPINION STATEMENT: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with multiple chemotherapeutic agents. CIPN may have a detrimental impact on patients' quality of life and functional ability, as well as result in chemotherapy dose reductions. Although symptoms of CIPN can improve with treatment completion, symptoms may persist. Currently, the treatment options for CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has the most evidence supporting its use in the treatment of CIPN. Other agents with potential benefit for the treatment of established CIPN include gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel consisting of the combination of amitriptyline, ketamine, and baclofen; none of these, however, has been proven to be helpful and ongoing/future studies may well show that they are not beneficial. The use of these agents is often based on their efficacy in the treatment of non-CIPN neuropathic pain, but this does not necessarily mean that they will be helpful for CIPN-related symptoms. Other nonpharmacologic interventions including acupuncture and Scrambler therapy are supported by positive preliminary data; however, further larger, placebo-controlled trial data are needed to confirm or refute their effectiveness.",
author = "Pachman, {Deirdre R.} and James Watson and Loprinzi, {Charles Lawrence}",
year = "2014",
month = "12",
day = "1",
doi = "10.1007/s11864-014-0303-7",
language = "English (US)",
volume = "15",
pages = "567--580",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Therapeutic strategies for cancer treatment related peripheral neuropathies

AU - Pachman, Deirdre R.

AU - Watson, James

AU - Loprinzi, Charles Lawrence

PY - 2014/12/1

Y1 - 2014/12/1

N2 - OPINION STATEMENT: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with multiple chemotherapeutic agents. CIPN may have a detrimental impact on patients' quality of life and functional ability, as well as result in chemotherapy dose reductions. Although symptoms of CIPN can improve with treatment completion, symptoms may persist. Currently, the treatment options for CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has the most evidence supporting its use in the treatment of CIPN. Other agents with potential benefit for the treatment of established CIPN include gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel consisting of the combination of amitriptyline, ketamine, and baclofen; none of these, however, has been proven to be helpful and ongoing/future studies may well show that they are not beneficial. The use of these agents is often based on their efficacy in the treatment of non-CIPN neuropathic pain, but this does not necessarily mean that they will be helpful for CIPN-related symptoms. Other nonpharmacologic interventions including acupuncture and Scrambler therapy are supported by positive preliminary data; however, further larger, placebo-controlled trial data are needed to confirm or refute their effectiveness.

AB - OPINION STATEMENT: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with multiple chemotherapeutic agents. CIPN may have a detrimental impact on patients' quality of life and functional ability, as well as result in chemotherapy dose reductions. Although symptoms of CIPN can improve with treatment completion, symptoms may persist. Currently, the treatment options for CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has the most evidence supporting its use in the treatment of CIPN. Other agents with potential benefit for the treatment of established CIPN include gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel consisting of the combination of amitriptyline, ketamine, and baclofen; none of these, however, has been proven to be helpful and ongoing/future studies may well show that they are not beneficial. The use of these agents is often based on their efficacy in the treatment of non-CIPN neuropathic pain, but this does not necessarily mean that they will be helpful for CIPN-related symptoms. Other nonpharmacologic interventions including acupuncture and Scrambler therapy are supported by positive preliminary data; however, further larger, placebo-controlled trial data are needed to confirm or refute their effectiveness.

UR - http://www.scopus.com/inward/record.url?scp=84932144727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932144727&partnerID=8YFLogxK

U2 - 10.1007/s11864-014-0303-7

DO - 10.1007/s11864-014-0303-7

M3 - Article

C2 - 25119581

AN - SCOPUS:84932144727

VL - 15

SP - 567

EP - 580

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 4

ER -